{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:44:32Z","timestamp":1789969472646,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,12,17]],"date-time":"2011-12-17T00:00:00Z","timestamp":1324080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Pemphigus is a potentially fatal autoimmune epidermal bullous disorder. Various treatment modalities have been described to treat pemphigus. In cases where the disease fails to respond to conventional therapy, rituximab has been shown to be effective.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To study the efficacy of rituximab in the treatment of resistant or severe pemphigus in Indian patients.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Patients with pemphigus were treated with intravenous rituximab 1000\u2003mg in adults or 375\u2003mg\/m<jats:sup>2<\/jats:sup> body surface area in children by two doses, 15\u2003days apart in this open labelled pilot study. Anti\u2010desmoglein1 (anti\u2010Dsg1) antibodies and anti\u2010desmoglein3 (anti\u2010Dsg3) antibodies were measured at the start of therapy and at the end of the follow\u2010up period. The outcome was studied in terms of control of disease activity (CD), complete remission (CR), partial remission (PR) and time to disease control (TDC) as defined by the consensus statement from the International Pemphigus Committee.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> A total of 9 (90%) of 10 patients responded to the treatment. Three (30%) had CR of disease and were off all treatment. Four (40%) patients had CR and were on low dose oral prednisolone. Two (20%) patients had PR and were on low dose prednisolone. One patient died of sepsis. The mean TDC was 8\u2003weeks. Response to treatment showed good correlation with index values of anti\u2010Dsg1 antibody. Infusion\u2010related angioedema and sepsis were seen as complications due to rituximab administration.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Rituximab is effective in treating resistant and severe pemphigus in Indian patients. Acute complications can occur during rituximab infusion and require close monitoring.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2011.04391.x","type":"journal-article","created":{"date-parts":[[2011,12,17]],"date-time":"2011-12-17T07:56:36Z","timestamp":1324108596000},"source":"Crossref","is-referenced-by-count":46,"title":["Efficacy and safety of rituximab treatment in Indian pemphigus patients"],"prefix":"10.1111","volume":"27","author":[{"given":"A.J.","family":"Kanwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tsuruta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Vinay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Dainichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,12,17]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1990.tb04767.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.82396"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1996.03890260105016"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-007-8021-6"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04744.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126273"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05580.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1997.12.177"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.2174\/187153008783928370"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.032"},{"key":"e_1_2_6_14_2","article-title":"Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone, and azathioprine\/mycophenolate mofetil: a pilot study of 23 patients","author":"Kasperkiewicz M","year":"2011","journal-title":"Br J Dermatol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062930"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.8.1033"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067752"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-002-0367-2"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.4.2010"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/7140.2006.00010"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06602.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000057886"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07800.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.9"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2009.06.018"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1994.tb01811.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2005.00118.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1994.tb00561.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0020-7292(93)90635-A"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2011.04391.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2011.04391.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T06:47:08Z","timestamp":1697352428000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2011.04391.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,17]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1468-3083.2011.04391.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04391.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,17]]}}}